<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CA59D75D-1AD9-4235-8F35-4E7E6E68EB81"><gtr:id>CA59D75D-1AD9-4235-8F35-4E7E6E68EB81</gtr:id><gtr:name>Norwegian University of Science and Technology (NTNU)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1EC5A569-85E9-44B3-AD1F-049F1003C9C6"><gtr:id>1EC5A569-85E9-44B3-AD1F-049F1003C9C6</gtr:id><gtr:name>University of Barcelona</gtr:name><gtr:address><gtr:line1>Universidad de Barcelona</gtr:line1><gtr:line2>Av Diagonal 647</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CA59D75D-1AD9-4235-8F35-4E7E6E68EB81"><gtr:id>CA59D75D-1AD9-4235-8F35-4E7E6E68EB81</gtr:id><gtr:name>Norwegian University of Science and Technology (NTNU)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1EC5A569-85E9-44B3-AD1F-049F1003C9C6"><gtr:id>1EC5A569-85E9-44B3-AD1F-049F1003C9C6</gtr:id><gtr:name>University of Barcelona</gtr:name><gtr:address><gtr:line1>Universidad de Barcelona</gtr:line1><gtr:line2>Av Diagonal 647</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8C34EA5B-ECE7-411E-B4F8-56A47498AB21"><gtr:id>8C34EA5B-ECE7-411E-B4F8-56A47498AB21</gtr:id><gtr:firstName>Mariia</gtr:firstName><gtr:surname>Yuneva</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_1202%2F4"><gtr:id>A33BFB4F-7715-4C03-8CFD-C361D28CBA9A</gtr:id><gtr:title>Identifying the role of metabolism in oncogene-induced tumorigenesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_1202/4</gtr:grantReference><gtr:abstractText>It is well known that tumours utilize nutrients differently than normal tissues. This difference may represent an opportunity for new anti-cancer therapeutic strategies. Our previous work showed that the way how tumours use various nutrients depends on which genetic changes they carry. Our goal is to understand how specific genetic lesions determine metabolic changes and nutrient requirement in tumours. In order to do that we will use animal models where tumours can be induced by specific genetic events. We will investigate how metabolism is changed in these tumours. To evaluate the requirement of this changes for tumour development we will use animal models in which the activity of metabolic pathways can be manipulated. Our results should allow us to develop new strategies to treat tumours carrying specific lesions.</gtr:abstractText><gtr:technicalSummary>Metabolic changes are thought to provide tumour cells with a proliferation and survival advantage over healthy cells. However, these alterations can also make tumour cells selectively dependent upon certain nutrients and metabolic pathways, making tumour metabolism an attractive therapeutic target. We demonstrated that both the genetic lesions and the tissue of origin are critical factors that determine tumour metabolism. However, the relationship between these factors and their contributions to the metabolic requirements of different tumour types in the context of the whole organism remain largely unknown.
 We will use mouse models and stable isotope-based metabolomics approaches to investigate how metabolism is changed in tumours induced by specific pro-tumorigenic events in various mammalian tissues. We will further investigate the requirement of these changes for initiation and progression of oncogene-induced tumorigenesis by using animal models where the expression of enzymes regulating tumor-specific metabolic pathways can be manipulated in tissue-specific and time-specific manners. We will us in vivo and in vitro approaches to understand the molecular mechanisms of tissue-specific regulation of metabolic pathways by different oncogenes as well as how oncogenes induce the metabolic dependence of transformed cells. Finally, we will explore the relationship between oncogenes and metabolic changes in various types of human cancers. Our studies should be able to provide new potential therapeutic targets tailored to specific types of cancers.</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-11-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1012726</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Francisco</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>The role of metabolic changes in liver cancer</gtr:description><gtr:id>E39F9D58-67DF-4C56-80A9-51D1EDDBEB14</gtr:id><gtr:impact>At least one paper is expected.</gtr:impact><gtr:outcomeId>5462291f5ce6b4.27514609-1</gtr:outcomeId><gtr:partnerContribution>Creating models of oncogene-induced liver tumors. Manipulating the expression of proteins of interest in these tumors.</gtr:partnerContribution><gtr:piContribution>Evaluating metabolic changes in oncogene-induced liver tumors. Evaluating metabolic changes in liver tumors in which metabolic enzymes have been manipulated by genetic methods.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Barcelona (UB)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>Faculty of Biology</gtr:department><gtr:description>CDK inhibition and metabolism</gtr:description><gtr:id>D8BC3442-CC81-40D6-8292-9D4531FBA184</gtr:id><gtr:impact>The collaboration will result in at least one publication.</gtr:impact><gtr:outcomeId>FbnjxCgzDZZ-1</gtr:outcomeId><gtr:partnerContribution>The collaborator's lab is performing further experiments and analyzing the samples using the equipment available in their laboratory.</gtr:partnerContribution><gtr:piContribution>My group hosted students from collaborator's laboratory. During their stay we created the tools required for the project as well as did some key experiments using the equipment and techniques available in my laboratory. We actively participate in the discussion of the data and planning the experiments.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>Metabolic changes in colorectal tumors</gtr:description><gtr:id>E5F9AB8D-5EED-436C-96B4-AA9C4EDEC652</gtr:id><gtr:impact>At least one paper is expected</gtr:impact><gtr:outcomeId>546227fc5888b7.03106247-1</gtr:outcomeId><gtr:partnerContribution>They are providing an ex vivo system as well as consulting on methods to manipulate the proteins of interests in this system.</gtr:partnerContribution><gtr:piContribution>We are evaluating the metabolic changes induced by different genetic lesions in in vivo and ex vivo models of colorectal cancers. We are evaluating the requirement of these changes for tumorigenesis in colon and intestine.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Norwegian University of Science and Technology (NTNU)</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>Detection of metabolic changes in tumor samples by HR MAS MRS</gtr:description><gtr:id>4F5294FB-E76B-4C8F-A8D6-CE67C63BFCCD</gtr:id><gtr:impact>The collaboration should result in at least one publication.</gtr:impact><gtr:outcomeId>546537ff6ae264.65624128-1</gtr:outcomeId><gtr:partnerContribution>Employing HR MAS MRS our partners measure and analyse the activity of metabolic pathways in the samples we provide.</gtr:partnerContribution><gtr:piContribution>We are providing samples from normal tissues and tumours from the animals injected with stable isotope tracers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Until recently the changes in metabolism of tumors were mostly judge based on the changes of levels of genes or proteins. Stable isotopes are being used to analyze the activity of various metabolic pathways as well as the destiny of various metabolites. We are developing the methods to analyze the metabolic changes during tumorigenesis using stable isotopes in the settings of the whole organism. We are developing the methods for data collection, analysis and interpretation.</gtr:description><gtr:id>129A031D-9FA8-4A6A-B150-BF7D54F732C3</gtr:id><gtr:impact>The information obtained allows for the accurate evaluation of metabolic changes in the settings of the whole organism without the artifacts created by the tissue culture. Moreover the technique allows for the comparison of normal tissue and derived tumors simultaneously.</gtr:impact><gtr:outcomeId>g7hMSDQzSG3</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>In vivo metabolomics analysis of tumorigenesis</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The requirement of specific enzyme isoforms in tumorigenesis has been mainly addressed using shRNA techniques or small molecule inhibitors, none of which can insure the absolute specificity of the enzyme activity inhibition. Using transgenic mouse lines allows for absolute specificity of the protein expression and consequently its activity. The lines we are generating also allow for ablating the expression of the specific enzyme isoforms in specific tissue.</gtr:description><gtr:id>06A4896E-508E-4A51-8420-D94AA4E52F93</gtr:id><gtr:impact>While most of the existing data are obtained in tissue culture conditions, generated mouse models are allowing us to understand the role of specific metabolic pathways in tumorigenesis in the setting of the whole organism close to the situation of the human disease.</gtr:impact><gtr:outcomeId>U5NxM1YWcLR</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Transgenic mouse lines</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2DE54885-6257-4608-8527-5973F7B5FEE3</gtr:id><gtr:title>Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bfd09e5279e3a5a684b4d3321e04515"><gtr:id>9bfd09e5279e3a5a684b4d3321e04515</gtr:id><gtr:otherNames>Wang B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5465392206e822.86875588</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0612A38-1F8F-4EB7-AE8D-B8FA3C88A243</gtr:id><gtr:title>Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9927fdaed12c1a0e03560372859ff7ee"><gtr:id>9927fdaed12c1a0e03560372859ff7ee</gtr:id><gtr:otherNames>Timmerman LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>546538faa98fb4.28438840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C24BAD4-19A5-472E-8021-57E42895984C</gtr:id><gtr:title>SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cd97b4a1e149c4f95df16a9cd3b6324"><gtr:id>0cd97b4a1e149c4f95df16a9cd3b6324</gtr:id><gtr:otherNames>Li L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>546538ca605322.06924745</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_1202/4</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>